Precision Diagnostics

From a single serum sample, we quantify multiple biomarkers — known and newly discovered. Advanced. Automated. Affordable.

Learn more

AXINON® System

Using FDA-cleared technology, the AXINON®System is our core platform. It incorporates diagnostic testing algorithms into nuclear magnetic resonance (NMR) spectroscopy.

Learn more

Nephrology. |Renal Function Assessment.


New Renal Function Assay. |AXINON® GFR (NMR).

Precision Diagnostics.

This new kidney function assay combines two novel biomarkers, valine and myo-inositol, with creatinine and cystatin C using highly accurate nuclear magnetic resonance (NMR) spectroscopy.

A single result from this biomarker constellation generates a more accurate GFR result compared to standard eGFR equations.

  • Improves Accuracy: More closely correlates with measured GFR (mGFR) compared to traditional GFR equations
  • Overcomes Bias: Accounts for non-renal factors, i.e., comorbidities, age, race, BMI and muscle mass
  • Provides a Clearer Picture of GFR Status: Increases accuracy and confidence in kidney function research
  • Uses Exploratory Biomarker Mining: Enhances personalized medicine research

 

Frontiers | Serum myo-inositol and valine improve metabolomic-based estimated glomerular filtration rate among kidney transplant recipients (frontiersin.org)

Selected Publications

Meeusen J, Stämmler F, Dasari S, et al. (2022). Front. Med. 9:988989.

Fuhrmann M, Santamaria A, Scott, R, et al. (2022). Diagnostics 2022, 12(5), 1120.

Stämmler F, Grassi M, Meeusen JW, et al. (2021). Diagnostics (Basel). 2021 Dec 7;11(12):2291.

Ehrich J, Dubourg L, Hansson S, et al. (2021). Diagnostics (Basel). 2021 Feb 3;11(2):234

Research use only in the US and available as CE-labeled IVD in the EU.

Technology. |AXINON®System.

Easy. Fast. Efficient.

Nuclear magnetic resonance (NMR) spectroscopy is a proven and highly accurate test technology that assesses a variety of compounds at a molecular level.

For GFR(NMR), the generated signals from serum samples corresponds with concentrations of the targeted metabolites with results reported in mL/minute/1.73 m2.

Our FDA-cleared AXINON® System is the core technology platform we use to develop diagnostic tests for illnesses stemming from metabolic dysfunction, including chronic heart, kidney and liver diseases. This system incorporates diagnostic testing algorithms into nuclear magnetic resonance (NMR) spectroscopy for precise results.

To date, more than 3 million tests have been performed worldwide using Numares technology.

Technology


* For Research Use only in the United States. numares’ products are not yet available for sale within the United States; they have not yet been approved or cleared by the U.S. Food and Drug Administration.

GFR — One of the most important markers for identifying impaired renal function

  • Chronic kidney disease (CKD) is a common consequence of many medical conditions, and it's prevalence is rising.​​​​
  • Hypertension and diabetes mellitus — two main CKD causes. 
  • Glomerular Filtration Rate (GFR) is one of the most common tests used, and included in all standard blood panels assessing kidney function. 

Currently, GFR is based on an estimation using clinical data and blood-based biomarkers, like creatinine or cystatin C. GFR can either be measured (mGFR) by tracer methods or estimated (eGFR).

mGFR methods are elaborate and time-consuming, and eGFR lacks accuracy in a number of common clinical situations. Because of this, clinical decision-making is difficult, especially early when intervention may help slow progression to end-stage renal disease.

1. 2011–2014 National Health and Nutrition Examination Survey and the CKD Epidemiology Collaboration (CKD-EPI) equation.

You did not activate the necessary cookies for this content.

activate necessary cookies and show content